Supriya Rao, M.D., a board-certified physician in internal medicine, gastroenterology, obesity medicine, and lifestyle medicine in Boston
Patients should be monitored for tolerability during dose titration, and bile duct stones remain a rare possibility even without a gallbladder
The phase 2 dose-ranging trial (NCT02970942) included 320 individuals with histologically proven MASH and hepatic fibrosis F1-F3, randomizing them 3:3:3:1:1:1 to daily subcutaneous administration of semaglutide 0.1, 0.2, or 0.4 mg, or placebo for 72 weeks [18]
Extra or hidden expenses when the dose increases
Saxenda is an FDA-approved GLP-1 medication prescribed for chronic weight management